Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A0AVF1
UPID:
IFT56_HUMAN
Alternative names:
Tetratricopeptide repeat protein 26
Alternative UPACC:
A0AVF1; A4D1S3; B7Z5M0; C9J2N7; F8W724; Q9H9S8; Q9NTC0
Background:
Intraflagellar transport protein 56, also known as Tetratricopeptide repeat protein 26, plays a crucial role in the intraflagellar transport (IFT) complex B. This protein is essential for the transport of specific ciliary cargo proteins related to motility and is pivotal in maintaining the integrity of the IFT complex B, ensuring proper ciliary localization of its components. It is not required for IFT complex A ciliary localization or function but is vital for proper microtubule organization within the ciliary axoneme.
Therapeutic significance:
The protein's involvement in Biliary, renal, neurologic, and skeletal syndrome, a ciliopathy with multisystemic manifestations, underscores its therapeutic significance. Understanding the role of Intraflagellar transport protein 56 could open doors to potential therapeutic strategies for treating this complex syndrome, highlighting the importance of targeted research in this area.